BidaskClub upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a hold rating to a buy rating in a research report released on Friday, BidAskClub reports.

A number of other research firms also recently commented on SRPT. Cantor Fitzgerald increased their price objective on shares of Sarepta Therapeutics from $217.00 to $231.00 and gave the company an overweight rating in a research note on Thursday, February 28th. Morgan Stanley increased their price objective on shares of Sarepta Therapeutics from $161.00 to $169.00 and gave the company an overweight rating in a research note on Monday, March 4th. Citigroup increased their price objective on shares of Sarepta Therapeutics from $188.00 to $201.00 and gave the company a buy rating in a research note on Friday, March 1st. Nomura increased their price objective on shares of Sarepta Therapeutics from $205.00 to $230.00 and gave the company a buy rating in a research note on Thursday, February 28th. Finally, JMP Securities reiterated a buy rating and set a $270.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, February 27th. Twenty-one research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and an average target price of $201.71.

NASDAQ SRPT opened at $127.34 on Friday. Sarepta Therapeutics has a 12 month low of $95.21 and a 12 month high of $165.87. The company has a quick ratio of 11.15, a current ratio of 12.17 and a debt-to-equity ratio of 0.35. The company has a market cap of $9.63 billion, a P/E ratio of -23.32 and a beta of 1.95. The company’s fifty day moving average is $121.35.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.05) by $0.98. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. The firm had revenue of $87.01 million for the quarter, compared to the consensus estimate of $86.92 million. As a group, research analysts predict that Sarepta Therapeutics will post -4.36 EPS for the current fiscal year.

In related news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total value of $1,200,000.00. Following the sale, the director now directly owns 21,717 shares in the company, valued at approximately $2,606,040. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 6.60% of the company’s stock.

A number of large investors have recently modified their holdings of SRPT. BNP Paribas Arbitrage SA increased its stake in Sarepta Therapeutics by 3.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,676 shares of the biotechnology company’s stock valued at $319,000 after buying an additional 98 shares during the period. Public Employees Retirement Association of Colorado increased its stake in Sarepta Therapeutics by 0.8% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 12,966 shares of the biotechnology company’s stock valued at $1,415,000 after buying an additional 105 shares during the period. American International Group Inc. increased its stake in Sarepta Therapeutics by 7.3% during the 4th quarter. American International Group Inc. now owns 1,605 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 109 shares during the period. M&T Bank Corp increased its stake in Sarepta Therapeutics by 4.0% during the 4th quarter. M&T Bank Corp now owns 2,979 shares of the biotechnology company’s stock valued at $325,000 after buying an additional 114 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Sarepta Therapeutics by 13.5% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,384 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 165 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

See Also: How to build a Fibonacci channel

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.